Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase III trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.

Next Previous
X
Search
Trial Profile

Randomized phase III trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications B-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms RESORT

    • Most Recent Events

    • 30 Jan 2024 Status changed from active, no longer recruiting to completed.
    • 10 Dec 2013 Pharmacogenomic analysis of follicular lymphoma patients presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 10 Dec 2012 Patient-reported outcomes and QOL data (n=253) presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top